News
Lilly, Wegovy and Zepbound
Digest more
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback